Lilly will work with Cinda bio pharmaceutical to develop anticancer drugs

Lilly has reached a cooperation agreement with China Cinda biopharmaceutical (Suzhou) Co., Ltd to jointly develop at least three kinds of anti-cancer drugs, which will be one of the most extensive cooperation between large western pharmaceutical companies and Chinese biotechnology enterprises so far Working with Chinese companies will also help Lilly speed up the launch of new drugs in China The deal shows that despite recent resistance to growth in China, the pharmaceutical industry remains interested in the Chinese market Lilly said it would advance US $56 million to Chinese start-up innovent biology Inc to jointly develop at least three experimental anticancer drugs, one of which is in the charge of Lilly's research and development laboratory and the other two are in the charge of Xinda bio pharmaceutical Lilly may also pay more than $400 million if one of the drugs that Cinda biopharmaceuticals is responsible for R & D meets specific R & D and business goals This agreement enables Lilly to have a Chinese partner, which helps Lilly speed up the introduction of new biotech drugs in the Chinese market The agreement also expanded Lilly's footprint in two hot pharmaceutical areas, one is drugs that activate the immune system to fight cancer cells, and the other is bio generic drugs If regulatory approval is obtained, the two companies will work together to market drugs in China Lilly will be responsible for the marketing of overseas markets Sinda biopharmaceutical was founded in 2011, mainly focusing on the research and development of monoclonal antibody drugs The company is developing 10 new monoclonal antibody drugs and has obtained venture capital from investors such as Lilly's venture capital fund and fidelity, a large mutual fund Co development of at least three antitumor drugs under the agreement, Cinda will receive a down payment of US $56 million If the monoclonal antibody molecule of tumor immunotherapy in preclinical stage reaches a specific milestone in development, registration and sales, Lilly will also pay a milestone payment of more than $400 million for the product In the next decade, Lilly and Cinda will cooperate to launch at least three potential cancer treatment drugs, two of which are new drug varieties owned by Cinda and the other is new drug varieties owned by Lilly Three new indications include lymphoma, gastric cancer and lung cancer Cinda will be responsible for leading the development and production of these three potential drugs for the Chinese market, while Lilly will be responsible for the commercialization of these three drugs, and Cinda also has the right to jointly promote them This cooperation will not only provide new treatment methods for cancer patients, but also further enhance the share of the two companies in the Chinese anti-tumor drug market Xinda biology is a biopharmaceutical company focusing on the research and development of new antibody drugs Its treatment field covers cancer and autoimmune diseases, and it has completed a financing of 135 million US dollars Lilly, whose core business is new drug development, has a well-known anti-tumor drug product line including small molecules and monoclonal antibodies At present, its R & D scope covers a series of cancer fields such as breast cancer, colorectal cancer, liver cancer, non-small cell lung cancer treatment, etc Antibody medicine is a kind of biological medicine that has been paid close attention in recent years, which has great economic and social value However, there are high technical requirements and R & D barriers to develop antibody medicine At present, developed countries and regions such as the United States and the European Union have absolute advantages in antibody market The signing of the strategic agreement between Xinda and Lilly marks a breakthrough in the innovation level and product quality of China's high-end biological drugs Yu Dechao, co-founder and chairman of Cinda biology, said in a media interview earlier: "after the launch of the cooperative drugs, the existing international monopoly will be broken, the price is significantly lower than that of similar products abroad Patients not only have drugs to treat, but also can reduce the cost of treatment." About Xinda biopharmaceutical Xinda biology was founded in 2011 by Dr Yu Dechao, a national special expert of "thousand talents plan" It is committed to the development and production of new antibody drugs for the treatment of various difficult diseases endangering human health and life Since its establishment, Xinda biology has won the favor of famous venture capital institutions at home and abroad with its innovative research and development ideas and international operation mode, and has successfully completed the financing of 135 million US dollars Endowment.